Literature DB >> 2664365

Application of the Mayo primary biliary cirrhosis survival model to Mayo liver transplant patients.

P M Grambsch1, E R Dickson, R H Wiesner, A Langworthy.   

Abstract

Liver transplantation is considered lifesaving for selected patients with end-stage primary biliary cirrhosis (PBC). A mathematical model to predict survival in the patient with PBC who has not undergone transplantation would be valuable for improving selection of patients for and timing of transplantation and for providing control information for assessment of the efficacy of transplantation. The Cox regression method and data from 312 Mayo Clinic patients with PBC were used to develop a model based on age, total serum bilirubin, serum albumin, prothrombin time, and severity of edema. When cross-validated on an independent set of 106 Mayo patients, the model accurately predicted their survival. It was similar to two other published survival models in terms of risk measurement but had the advantage of not necessitating liver biopsy. The model was used to assess the efficacy of liver transplantation by comparing the Kaplan-Meier survival of 32 Mayo patients after transplantation with the average model prediction of survival without transplantation. Beyond 3 months after transplantation, Kaplan-Meier survival probabilities were significantly greater than control survival predicted by the model (P less than 0.001). Examples of using the model for aiding in selection of patients for and timing of transplantation are provided.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2664365     DOI: 10.1016/s0025-6196(12)65350-6

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  7 in total

1.  Accuracy of staging in primary biliary cirrhosis.

Authors:  M C Garrido; S G Hubscher
Journal:  J Clin Pathol       Date:  1996-07       Impact factor: 3.411

2.  A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia.

Authors:  Kenichi Hosonuma; Ken Sato; Yuichi Yamazaki; Masatoshi Yanagisawa; Hiroaki Hashizume; Norio Horiguchi; Satoru Kakizaki; Motoyasu Kusano; Masanobu Yamada
Journal:  Am J Gastroenterol       Date:  2015-03-03       Impact factor: 10.864

3.  Survival of anti-mitochondrial antibody-positive and -negative primary biliary cirrhosis patients on ursodeoxycholic acid treatment.

Authors:  Meri Koulentaki; Joanna Moscandrea; Philipos Dimoulios; Costas Chatzicostas; Elias A Kouroumalis
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

4.  Efficacy of hepatic transplantation in patients with primary sclerosing cholangitis.

Authors:  K M Abu-Elmagd; M Malinchoc; E R Dickson; J J Fung; P A Murtaugh; A L Langworthy; A J Demetris; R A Krom; D H Van Thiel; T E Starzl
Journal:  Surg Gynecol Obstet       Date:  1993-10

5.  Disappearance of Oral Lichen Planus After Liver Transplantation for Primary Biliary Cirrhosis and Immunosuppressive Therapy in a 63-year-Old Japanese Woman.

Authors:  Yumiko Nagao; Michio Sata
Journal:  Hepat Mon       Date:  2014-03-11       Impact factor: 0.660

6.  Risk factors for hepatic decompensation in patients with primary biliary cirrhosis.

Authors:  Tian-Yan Shi; Li-Na Zhang; Hua Chen; Li Wang; Min Shen; Xuan Zhang; Feng-Chun Zhang
Journal:  World J Gastroenterol       Date:  2013-02-21       Impact factor: 5.742

7.  Mixed effect machine learning: A framework for predicting longitudinal change in hemoglobin A1c.

Authors:  Che Ngufor; Holly Van Houten; Brian S Caffo; Nilay D Shah; Rozalina G McCoy
Journal:  J Biomed Inform       Date:  2018-09-04       Impact factor: 6.317

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.